Literature DB >> 2541748

Patterns of antibody recognition of selected conserved amino acid sequences from the HIV envelope in sera from different stages of HIV infection.

A Shafferman1, J Lennox, H Grosfeld, J Sadoff, R R Redfield, D S Burke.   

Abstract

A total of six amino acid sequences encoded in conserved regions of the HIV-env (three from gp120 and three from gp41) were selected as potential antigenic domains. These sequences (11-20 amino acids) were fused to the NH2 terminus of beta-galactosidase by recombinant DNA techniques, and the purified chimeric proteins were used to titer (by immunodots) 75 sera from HIV-infected individuals of various stages. All the HIV antigens were recognized by some or all the HIV-seropositive sera but by none of the control sera. Of the three conserved domains in gp41, two are highly immunodominant. All (100%) HIV-seropositive sera reacted with one of these immunodominant domains in titers (approximately 1:100,000) almost two orders of magnitude higher than any other tested domain. This emphasizes the diagnostic value of the epitopes (ERYLKDQLLGIWGCSGKLIC) previously (see Refs. 11 and 12) identified in this domain. A decrease in average antibody titers is observed in late stages of infection for all the antigens tested, yet distribution of antibody reactivity was independent of stage for only three of the six domains. A significantly higher proportion of reactivity of seropositive sera in early stage (62%) compared with late stage (11%) of infection was found for a domain (NVTENFNMWKN) mapped at the NH2 terminus of gp120; serum antibody reactivity with this domain also correlated with a lack of culturable HIV in blood mononuclear cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2541748     DOI: 10.1089/aid.1989.5.33

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

1.  Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Authors:  J A Kovacs; M B Vasudevachari; M Easter; R T Davey; J Falloon; M A Polis; J A Metcalf; N Salzman; M Baseler; G E Smith
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

2.  Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees.

Authors:  R Q Warren; H Wolf; K R Shuler; J W Eichberg; R A Zajac; R N Boswell; P Kanda; R C Kennedy
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

3.  Serologically defined linear epitopes in the E2 envelope glycoprotein of Semliki Forest virus.

Authors:  N Ariel; S Lehrer; E Elhanaty; T Sabo; P Brodt; B Lachmi; D Katz; R Levin; H Grosfeld; B Velan
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

4.  Patterns of antibody reactivity to selected human immunodeficiency virus type 1 (HIV-1) gp160 epitopes infected individuals grouped according to CD4+ cell levels.

Authors:  R Q Warren; H Wolf; R A Zajac; R N Boswell; P Kanda; R C Kennedy
Journal:  J Clin Immunol       Date:  1991-01       Impact factor: 8.317

5.  Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160.

Authors:  A Benjouad; J C Gluckman; H Rochat; L Montagnier; E Bahraoui
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

6.  Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences.

Authors:  A Shafferman; P B Jahrling; R E Benveniste; M G Lewis; T J Phipps; F Eden-McCutchan; J Sadoff; G A Eddy; D S Burke
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

7.  Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.

Authors:  J P Moore; D D Ho
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

8.  Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.

Authors:  A Benjouad; J C Gluckman; L Montagnier; E Bahraoui
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.